drugset / Trial / NCT06735391
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitive mutations.
Timeline
- Start
- 2024-10-23
- Primary completion
- 2026-09-30
- Completion
- 2029-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BECOTATUG | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Osimertinib | Small molecule | 80 mg | Oral |
Indications
No indication recorded.